Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNA, U6 small nuclear 230, pseudogene (**RNU6-230P**) is a pseudogene derived from the U6 small nuclear RNA gene family, which plays an essential role in pre-mRNA splicing as part of the spliceosome[3]. Unlike its parent gene, RNU6-230P does not encode a functional RNA product and is generally considered nonfunctional in terms of direct biological processes. Pseudogenes such as RNU6-230P may sometimes have regulatory effects through competitive binding of microRNAs (as “ceRNAs”), but there is currently no direct evidence indicating a functional or disease-related role for RNU6-230P specifically[4]. Pseudogenes are typically not considered therapeutic targets, and RNU6-230P is not currently associated with any pharmacological interventions or established use as a biomarker. Misspelling or confusion with the active U6 snRNA molecule is possible, and care should be taken to distinguish functional snRNAs from pseudogene loci.
Not applicable (no known drugs target this pseudogene)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 230, pseudogene (RNU6-230P).